Compare · INSM vs LLY
INSM vs LLY
Side-by-side comparison of Insmed Incorporated (INSM) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INSM and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.07T, about 52.2x INSM ($20.42B).
- LLY has been more active in the news (16 items in the past 4 weeks vs 9 for INSM).
- Both have 25 recent analyst ratings on file.
- Company
- Insmed Incorporated
- Eli Lilly and Company
- Price
- $94.15-10.25%
- $1132.80+0.65%
- Market cap
- $20.42B
- $1.07T
- 1M return
- -
- +14.77%
- 1Y return
- -
- +46.44%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 9
- 16
- Recent ratings
- 25
- 25
Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest INSM
- Chief Operating Officer Adsett Roger sold $242,380 worth of shares (2,370 units at $102.27), decreasing direct ownership by 2% to 98,603 units (SEC Form 4) (tax liability)
- Chief Financial Officer Bonstein Sara sold $245,857 worth of shares (2,404 units at $102.27), decreasing direct ownership by 3% to 69,082 units (SEC Form 4) (tax withholding)
- Chief Legal Officer Smith Michael Alexander sold $220,801 worth of shares (2,159 units at $102.27), decreasing direct ownership by 5% to 39,454 units (SEC Form 4) (tax liability)
- Chief Medical Officer Flammer Martina M.D. sold $455,248 worth of shares (4,424 units at $102.90) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 60,486 units (SEC Form 4) to satisfy withholding obligation
- Chair and CEO Lewis William sold $777,763 worth of shares (7,605 units at $102.27), decreasing direct ownership by 3% to 265,432 units (SEC Form 4) (for tax liability)
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
- Chief Legal Officer Smith Michael Alexander sold $666,982 worth of shares (6,149 units at $108.47) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 41,613 units (SEC Form 4)
- Chair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $2,718,224 worth of shares (25,564 units at $106.33) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 273,037 units (SEC Form 4)
- SEC Form S-3ASR filed by Insmed Incorporated
Latest LLY
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial